June 23, 2009Nephrology Dialysis Transplantation
Low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis
Why the study?
Do low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis?
Population
203 prevalent haemodialysis patients, 56% men, median age 66 years, vintage time 29 months.
Comparison
Low levels of IgM antibodies against… vs High levels of anti-PC (above median 42.1 U/mL)
Design
Cohort
Follow-up
mean 29 (14-58) months
Authors
Discussion
Loading...
Member takes
Implication
Low anti-PC levels were associated with higher mortality in hemodialysis; hypothesis-generating and requires prospective validation before clinical use.
Structured PICO
Do low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis?
P
Population
203 prevalent haemodialysis (HD) patients, 56% men, median age 66 (IQR 51-74) years, vintage time 29 (15-58) months.
I
Intervention
Low levels of IgM antibodies against phosphorylcholine-A (anti-PC) (below median 42.1 U/mL)
C
Comparator
High levels of anti-PC (above median 42.1 U/mL)
O
Outcome
Mortality risk (death) over a mean follow-up of 29 monthshard clinical
Low levels of natural IgM antibodies against phosphorylcholine-A are an independent predictor of increased mortality in patients undergoing haemodialysis.
Cite This Study
Carrero et al. (2009) studied this question.